The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1229-1234.e4, December 2009

High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations

  • Lucie Blais, PhD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Lucie Blais, Université de Montréal, Faculté de pharmacie, CP 6128, succursale Centre-ville, Montréal (Québec), Canada H3C 3J7.
  • ,
  • Marie-France Beauchesne, PharmD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
  • ,
  • Catherine Lemière, MD, MSc

      Affiliations

    • Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
  • ,
  • Naoual Elftouh, MSc

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada

Received 23 July 2009; received in revised form 16 September 2009; accepted 17 September 2009. published online 12 November 2009.

Background

Although reassuring data exist on the use of low-to-moderate doses of inhaled corticosteroids (ICSs) during pregnancy, there are inadequate data for women receiving high doses.

Objective

To investigate the association between doses of ICS during the first trimester of pregnancy and the risk of congenital malformations among women with asthma.

Methods

We conducted a cohort study of 13,280 pregnancies of women with asthma (1990-2002) by linking 3 administrative databases from Quebec (Canada). By using generalized estimation equation models, we compared women taking >0 to 1000 μg/d ICS (beclomethasone dipropionate–chlorofluorocarbone equivalent) with women taking >1000 μg/d and those not taking ICSs. The main outcome measures were all and major congenital malformations.

Results

We identified 1257 infants with a congenital malformation (9.5%) and 782 infants with a major malformation (5.9%). We found that women who used >1000 μg/d ICS (n = 154) were significantly more likely (63%) to have a baby with a malformation than the 4392 women who used >0 to 1000 μg/d (adjusted risk ratio, 1.63; 95% CI, 1.02-2.60). On the other hand, women who used >0 to 1000 μg/d were not found to be more at risk than women who did not use ICSs during the first trimester (n = 8734). Nonsignificant trends of similar magnitude were found for major malformations.

Conclusions

Our study adds evidence on the safety of low-to-moderate doses of ICS taken during the first trimester but raises concerns about high doses. However, we cannot rule out the possibility of residual confounding by severity in this association.

Key words: Asthma, pregnancy, inhaled corticosteroids, congenital malformations, cohort study

Abbreviations used: ED, Emergency department, ICD-9, International Classification of Diseases, Ninth Revision, ICS, Inhaled corticosteroid, ISQ, Institut de la statistique du Québec, MED-ECHO, Maintenance et Exploitation des données pour l'étude de la clientèle hospitalière, OR, Odds ratio, RAMQ, Régie de l'assurance-maladie du Québec, RR, Risk ratio

 

 L.B. and C.L. are the recipients of a Salary Award from the Fonds de la recherche en santé du Québec (FRSQ).This study was funded through grants received from the FRSQ, the Canadian Institutes of Health Research, and the Canadian Foundation for Innovation. The research was completely independent from the funders.

 Disclosure of potential conflict of interest: L. Blais receives research support from AstraZeneca and Amgen. M.-F. Beauchesne receives honoraria for CE programs from AstraZeneca, GSK Canada, and BI/Pfizer Canada. C. Lemière receives research support from NIOSH and GlaxoSmithKline. The other author declares that she has no conflict of interest.

PII: S0091-6749(09)01414-6

doi:10.1016/j.jaci.2009.09.025

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1229-1234.e4, December 2009